Provided by Tiger Trade Technology Pte. Ltd.

Karyopharm Therapeutics

2.06
+0.190010.16%
Post-market: 2.070.0100+0.49%19:59 EDT
Volume:2.03M
Turnover:4.06M
Market Cap:46.69M
PE:-0.16
High:2.14
Open:1.91
Low:1.79
Close:1.87
52wk High:10.99
52wk Low:1.79
Shares:22.66M
Float Shares:17.07M
Volume Ratio:2.21
T/O Rate:11.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0816
EPS(LYR):-17.9300
ROE:-891.05%
ROA:-47.61%
PB:-0.14
PE(LYR):-0.11

Loading ...

U.S. RESEARCH ROUNDUP-East West Bancorp, Reliance, S&P Global

Reuters
·
Apr 27

Karyopharm Therapeutics Inc : Piper Sandler Raises Target Price to $16 From $8

THOMSON REUTERS
·
Apr 27

Karyopharm Phase 3 SENTRY myelofibrosis trial results set for ASCO late-breaking oral presentation

Reuters
·
Apr 21

Karyopharm publishes corporate presentation highlighting Phase 3 selinexor readouts in myelofibrosis

Reuters
·
Apr 16

RBC Capital Adjusts Karyopharm Therapeutics PT to $16 From $23, Maintains Outperform Rating

MT Newswires Live
·
Apr 07

Karyopharm Therapeutics Price Target Cut to $8.00/Share From $12.00 by Piper Sandler

Dow Jones
·
Mar 31

Karyopharm Therapeutics Inc : Piper Sandler Cuts Target Price to $8 From $12

THOMSON REUTERS
·
Mar 30

Karyopharm Therapeutics sells 1,030,354 shares at $6.785; gross proceeds rise to about $30 million in RA Capital private placement

Reuters
·
Mar 27

BUZZ-Street View: Karyopharm's cancer drug trial results limit regulatory odds

Reuters
·
Mar 25

Karyopharm Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 25

Sector Update: Health Care Stocks Advance Late Afternoon

MT Newswires Live
·
Mar 25

Karyopharm Therapeutics Falls As Pivotal Trial Hits Spleen Goal But Misses Symptom Mark

Benzinga
·
Mar 25

Sector Update: Health Care Stocks Mixed Pre-Bell Tuesday

MT Newswires Live
·
Mar 24

Karyopharm Therapeutics Shares Reverse Course; NOW Down 10% Premarket

THOMSON REUTERS
·
Mar 24

Karyopharm Therapeutics Shares up 16% Premarket After Co's Blood Cancer Drug Meets One of Two Main Goals in Late‑Stage Study

THOMSON REUTERS
·
Mar 24

Karyopharm Therapeutics' blood cancer drug meets one of two main goals in study

Reuters
·
Mar 24

Karyopharm’s Phase 3 SENTRY trial meets first co-primary endpoint

TIPRANKS
·
Mar 24

Karyopharm prices USD 30 million private placement with RA Capital

Reuters
·
Mar 24

Karyopharm SENTRY Phase 3 trial in myelofibrosis meets SVR35 endpoint with 22 percentage-point gain at week 24

Reuters
·
Mar 24

Karyopharm Announces $30 Million Private Placement With Ra Capital

THOMSON REUTERS
·
Mar 24